Charles Lowe, NP
Nurse Practitioner · Mc Lean, VANPI 1740883479
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.6% of the total across 265 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Medtronic at 40.0% of the total. Reporting peaked in 2023 at $2,630 and has fallen 99.3% since, to $19 in 2025. Among nurse practitioner clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 265 payments — averaging $23.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Collegium Pharmaceutical, Inc.$845
- AbbVie$718
- Vertos Medical, Inc.$552
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$536
- Boston Scientific$238
- plus $844 from 16 others
What the payments were for
- Consulting fees$5258%
- Food & beverage$5,69692%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 103 | $2,488 |
| Collegium Pharmaceutical, Inc. | 49 | $845 |
| AbbVie(2 entities) | 29 | $718 |
| Vertos Medical, Inc. | 4 | $552 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 41 | $536 |
| Boston Scientific | 4 | $238 |
| Averitas Pharma Inc. | 11 | $229 |
| Relievant Medsystems, Inc. | 3 | $216 |
| Vertex | 2 | $52 |
| Azurity Pharmaceuticals, Inc. | 3 | $49 |
| Biodelivery Sciences International, Inc. | 3 | $41 |
| Amgen | 2 | $31 |
| Nevro Corp. | 1 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Curonix LLC | 2 | $28 |
| Bioventus LLC | 1 | $23 |
| Fidia Pharma USA Inc. | 1 | $23 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
| Pacira Pharmaceuticals Incorporated | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Pfizer | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$602
- mild Device Kit$525
- INTELLIS ADAPTIVESTIM$366
- SYNCHROMEDII$125
- GENERAL - THERAPIES$123
- Vanta$122
- KYPHON EXPRESS II KYPHOPAK TRAY$100
How this compares
$6,221 in reported general payments places this provider in the 95th percentile of 2,166 nurse practitioner providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 43 | $24,653 |
| BelbucaBuprenorphine Hcl | 26 | $22,394 |
| OxycontinOxycodone Hcl | 30 | $19,748 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 151 | $3,600 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 115 | $3,177 |
| Lidocaine | 25 | $2,917 |
| Gabapentin | 180 | $2,298 |
| Oxycodone Hcl | 127 | $2,064 |
| Chlorzoxazone | 21 | $1,703 |
| Pregabalin | 66 | $1,434 |
| Morphine Sulfate ErMorphine Sulfate | 51 | $1,182 |
| Cyclobenzaprine Hcl | 46 | $1,178 |
| Naloxone Hcl | 18 | $925 |
| Celecoxib | 24 | $560 |
| Tramadol Hcl | 30 | $192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $845 | $47,04769 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,166 nurse practitioner providers in Virginia.
Other nurse practitioner in Mc Lean
- Samantha FoxGate City$207K
- Mikel GrayCharlottesville$174K
- Kevin BrigleRichmond$166K
- Denese GomesRichmond$126K
- Ashley CarmenAlexandria$99K
- Rachel AndersonCharlottesville$90K
- Megan FrancisArlington$81K
- Elizabeth WilletteNorfolk$58K
- Lacey LyleSuffolk$50K
- Kristin AustriaVirginia Beach$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.